Caldesmon
| Caldesmon | ||
|---|---|---|
| Properties of human protein | ||
| Mass / length primary structure | 793 amino acids , 93,231 Da | |
| Identifier | ||
| External IDs | ||
| Orthologue | ||
| human | mouse | |
| Entrez | 800 | 109624 |
| Ensemble | ENSG00000122786 | ENSMUSG00000029761 |
| UniProt | Q05682 | Q05682 |
| Refseq (mRNA) | NM_004342.6 | NM_001347100.1 |
| Refseq (protein) | NP_004333.1 | NP_001334029.1 |
| Gene locus | ||
| PubMed search | 800 |
109624
|
Caldesmon is a protein and participates in the regulation of the cytoskeleton in vertebrates .
properties
Caldesmon is a calmodulin- binding protein. The isoform 1 is mainly in the smooth muscle formed while isoforms 2 to 5 in different cell types is formed. Caldesmon is not made in the heart and skeletal muscles .
Caldesmon continues to bind to actin , myosin, and tropomyosin, and forms a link between actin and myosin. It promotes the binding of two tropomyosins to actin, which stabilizes actin filaments . In smooth muscles, caldesmon inhibits actomyosin ATPase by binding to F-actin. This inhibition is increased by tropomyosin and decreased by calcium- calmodulin. Caldesmon is also involved in mitosis . Caldesmon is phosphorylated by PAHs , which reduces the binding affinity for calmodulin by a factor of 10 and the inhibition of ATPase significantly decreases. The phosphorylation is removed by the caldesmon phosphatase. Furthermore, caldesmon inhibits cell growth , cell migration and the exocytosis of matrix metalloproteinases on the cell membrane .
Web links
Individual evidence
- ↑ RE Novy, JL Lin, JJ Lin: Characterization of cDNA clones encoding a human fibroblast caldesmon isoform and analysis of caldesmon expression in normal and transformed cells. In: The Journal of biological chemistry. Volume 266, Number 25, September 1991, pp. 16917-16924, PMID 1885618 .
- ↑ CL Wang: Caldesmon and the regulation of cytoskeletal functions. In: Advances in Experimental Medicine and Biology . Volume 644, 2008, pp. 250-272, PMID 19209827 , PMC 2975104 (free full text).
- ↑ T. Mayanagi, K. Sobue: Diversification of caldesmon-linked actin cytoskeleton in cell motility. In: Cell adhesion & migration. Volume 5, Number 2, 2011 Mar-Apr, pp. 150-159, PMID 21350330 , PMC 3084981 (free full text).
- ↑ CM Hai: Caldesmon as a therapeutic target for proliferative vascular diseases. In: Mini reviews in medicinal chemistry. Volume 8, Number 12, October 2008, pp. 1209-1213, PMID 18855735 , PMC 4322390 (free full text).